U.S. markets close in 5 hours 57 minutes

Bioanalytical Systems, Inc. (BASI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
18.05+1.01 (+5.93%)
As of 9:59AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close17.04
Open17.18
Bid17.55 x 1000
Ask18.04 x 1200
Day's Range17.13 - 18.05
52 Week Range3.05 - 18.60
Volume18,870
Avg. Volume112,306
Market Cap200.92M
Beta (5Y Monthly)1.95
PE Ratio (TTM)N/A
EPS (TTM)-0.33
Earnings DateMay 12, 2021 - May 17, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • The President of Bioanalytical Systems, Inc. (NASDAQ:BASI), Robert Leasure, Just Bought 2.2% More Shares
    Simply Wall St.

    The President of Bioanalytical Systems, Inc. (NASDAQ:BASI), Robert Leasure, Just Bought 2.2% More Shares

    Whilst it may not be a huge deal, we thought it was good to see that the Bioanalytical Systems, Inc. ( NASDAQ:BASI...

  • Bioanalytical Systems, Inc., doing business as Inotiv, Invests in Laboratory Infrastructure and Data and Study Management Technologies
    GlobeNewswire

    Bioanalytical Systems, Inc., doing business as Inotiv, Invests in Laboratory Infrastructure and Data and Study Management Technologies

    WEST LAFAYETTE, Ind., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (the “Company”, “We”, “Our” or “Inotiv”), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services, today announced additional investments in laboratory infrastructure and data and study management technologies in order to support the Company’s growth strategy and service delivery goals for clients. In November 2020, Inotiv hired Todd Francisco as Director, Laboratory Information Systems, to assist with Company directives related to laboratory infrastructure and data and study management technologies. Inotiv recently partnered with Centric Consulting, LLC, a digital, business and technology solutions company, to facilitate the design and implementation of an enterprise technology solution for study management. The Company believes that integrating study management activities and migrating multiple legacy systems to a new, singular platform, will improve processes, enable a more seamless, automated workflow and improve client deliverables. Concurrently, Inotiv has invested in software solutions to support existing internal expertise in the area of SEND (Standard for Exchange of Nonclinical Data) data management and delivery, with the near-term objective to support and grow most of this function with internal resources, as some of these services were previously outsourced. Through involvement with organizations like PHUSE (Pharmaceutical User Software Exchange) and its working groups, the Company remains abreast of discussions about the management and implementation of this standard. The Company believes its experience, expertise, and ongoing exchange of knowledge in this area will benefit their clients by enhancing their ability to present data in the best possible light, in conformity with evolving regulatory standards. “We are a services company, focused on delivering high quality data to our clients. Having one scalable, data and study management platform is fundamental to our success. We believe our investments in infrastructure and technology will support future growth, enhance communication internally, reduce our outsourcing of services, and further bolster our ability to service our clients,” said Company President and Chief Executive Officer Robert Leasure, Jr. “These efforts support our fundamental goals of enhancing our work environment and delivering exceptional client experience—always.” Over the past several years, the Company has worked to integrate processes and coordinate teams and services across their multiple sites to move from a collective of broad responsibilities and disparate systems to more focused and integrated teams, aligned with client and internal needs. About the Company Bioanalytical Systems, Inc., doing business as Inotiv, is a pharmaceutical development company providing contract research services and monitoring instruments to emerging pharmaceutical companies and the world's leading drug development companies and medical research organizations. The Company focuses on developing innovative services supporting its clients’ discovery and development objectives for improved decision-making and accelerated goal attainment. The Company’s products focus on increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Visit inotivco.com for more information about the Company. This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof, the impact of the COVID-19 pandemic on the economy, demand for our services and products and our operations, including the measures taken by governmental authorities to address the pandemic, which may precipitate or exacerbate other risks and/or uncertainties and various other market and operating risks, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission. Company ContactInvestor RelationsBioanalytical Systems, Inc., dba InotivThe Equity Group Inc.Beth A. Taylor, Chief Financial OfficerKalle Ahl, CFA(765) 497-8381(212) 836-9614btaylor@inotivco.comkahl@equityny.com Devin Sullivan (212) 836-9608 dsullivan@equityny.com

  • Bioanalytical Systems, Inc., doing business as Inotiv, Appoints Greg Beattie as Chief Operating Officer
    GlobeNewswire

    Bioanalytical Systems, Inc., doing business as Inotiv, Appoints Greg Beattie as Chief Operating Officer

    Greg Beattie Bioanalytical Systems, Inc., doing business as Inotiv, Appoints Greg Beattie as Chief Operating Officer WEST LAFAYETTE, Ind., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (the “Company”, “We”, “Our” or “Inotiv”), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services, today announced the appointment of Greg Beattie as Chief Operating Officer of the Company, effective February 15, 2021. Mr. Beattie brings more than 30 years of contract research experience to the Company, including more than two decades in operational leadership roles at Charles River Laboratories, where he drove growth and profitability across multiple business units. During his career at Charles River Laboratories, Mr. Beattie held Corporate Vice President positions leading business units within all three of Charles River Laboratories’ segments of operations (Discovery and Safety Assessment, Research Models and Services and Manufacturing Support). In these roles, Mr. Beattie was responsible for driving operational performance for divisions with revenue in excess of $100 million. Among his most significant accomplishments was leadership of the design, construction and staffing of one of the largest preclinical facilities in the world in Reno, Nevada. Mr Beattie also led a new business venture (Charles River Accelerator and Development Lab), and integrated an expanding Biologics Testing Solutions business. Mr. Beattie holds a Bachelor of Science degree in Biology from McGill University and a Master of Science degree in Experimental Health Sciences from Université du Quebéc, and graduated from the Kellog Management Institute program at Northwestern University. Mr. Beattie held certification as Diplomate of the American Board of Toxicology (DABT) between 1999 and 2019. “We continue to attract high-caliber leaders to our team and look forward to welcoming Greg as another talented member of Inotiv,” said Robert Leasure, Jr., the Company's President and Chief Executive Officer. “He is an accomplished executive with a proven industry track record, and brings extensive experience in strategic planning, process improvement, enterprise-wide system implementation, leadership development and team building.” Mr. Beattie commented, “I am very excited to join Inotiv at this pivotal point in its growth trajectory and I look forward to helping the team drive value-creation for our stakeholders. Inotiv has a reputation for outstanding talent, a strong client-service orientation and a winning culture, which should provide an excellent foundation to continue to build upon.” About the Company Bioanalytical Systems, Inc., doing business as Inotiv, is a pharmaceutical development company providing contract research services and monitoring instruments to emerging pharmaceutical companies and the world's leading drug development companies and medical research organizations. The Company focuses on developing innovative services supporting its clients’ discovery and development objectives for improved decision-making and accelerated goal attainment. The Company’s products focus on increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Visit inotivco.com for more information about the Company. This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof, the impact of the COVID-19 pandemic on the economy, demand for our services and products and our operations, including the measures taken by governmental authorities to address the pandemic, which may precipitate or exacerbate other risks and/or uncertainties and various other market and operating risks, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission. Company Contact Investor RelationsBioanalytical Systems, Inc., dba Inotiv The Equity Group Inc.Beth A. Taylor, Chief Financial Officer Kalle Ahl, CFA(765) 497-8381 (212) 836-9614btaylor@inotivco.com kahl@equityny.com Devin Sullivan (212) 836-9608 dsullivan@equityny.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/587eb23f-11a0-4879-a96f-01a4379900fd